Platform
Company
Coagulation
Review status
Currently under review
Pending specialist review and validation.
This test measures the activity of Factor VII, a vitamin K dependent clotting protein that helps your blood form a stable clot. Factor VII works early in the clotting cascade and is essential for starting the process when there is an injury. The result reflects how well Factor VII is functioning in your plasma, not just how much of the protein is present.
The term 1:10 refers to a dilution used by the laboratory method to ensure accurate measurement. It does not change the clinical meaning of the result. Your sample is collected in a light blue citrate tube and analyzed using a clot-based assay that compares your clotting response to a reference plasma.
Your clinician may order this test if you have unexplained bleeding, a prolonged prothrombin time, suspected vitamin K deficiency, or liver disease. It can also help diagnose congenital Factor VII deficiency, a rare inherited condition that can cause easy bruising, nosebleeds, or bleeding after procedures. In certain settings, it is used to assess recovery after vitamin K treatment or to monitor the effect of medications that reduce vitamin K activity.
Abnormal Factor VII activity can point to treatable causes. Low activity may occur with vitamin K deficiency, liver dysfunction, use of vitamin K antagonists such as warfarin, or rare inherited deficiency. Higher activity has been linked in some studies to a higher tendency for clotting, especially when combined with other risk factors. Understanding your Factor VII level helps guide further testing and care before surgeries, dental work, or other procedures.
Your report reflects how your Factor VII is functioning relative to a reference interval. A lower than expected result suggests an increased risk of bleeding and may prompt evaluation for vitamin K deficiency, liver disease, medication effects, or a congenital deficiency. If a deficiency is suspected, your clinician may order additional tests such as a mixing study, repeat factor assay, vitamin K assessment, or genetic testing when appropriate.
A higher than expected result can occur with inflammation, pregnancy, or estrogen therapy and may be considered alongside your personal and family history, other lab tests, and any clotting events. Results are interpreted in context with prothrombin time, INR, other factor assays, and your medications. Do not change or stop any treatment on your own. If results fall outside the expected range, your clinician will discuss next steps, which could include vitamin K replacement, medication adjustments, or further liver and coagulation testing.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Low vitamin K intake, malabsorption, or recent broad-spectrum antibiotics can reduce Factor VII activity. Consistent dietary vitamin K and addressing absorption issues help stabilize results.
Warfarin and other vitamin K antagonists lower Factor VII activity. Estrogen therapy, oral contraceptives, and some inflammatory states can raise it. Always list your medications and supplements.
Factor VII is made in the liver. Liver disease, bile duct obstruction, or acute liver injury can reduce production and activity, leading to lower results and potential bleeding risk.
Improper citrate tube fill, delays to centrifugation or freezing, extreme hematocrit, or heparin contamination can artifactually alter results. Proper phlebotomy technique reduces these errors.
Pregnancy and estrogen-containing therapies can increase Factor VII activity. Your provider will interpret results with your pregnancy status and hormone use in mind.
Acute-phase responses and tissue injury can shift Factor VII activity. Testing when you are clinically stable gives the most representative baseline.
References